Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received an average rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $21.40.

CLBT has been the topic of several recent research reports. DA Davidson initiated coverage on Cellebrite DI in a research note on Wednesday. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th.

Cellebrite DI Price Performance

CLBT opened at $13.20 on Friday. The business’s 50-day moving average price is $13.26 and its two-hundred day moving average price is $15.30. Cellebrite DI has a 1 year low of $11.02 and a 1 year high of $19.98. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of 47.14, a P/E/G ratio of 1.52 and a beta of 1.15.

Insider Activity

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 13,269 shares of company stock valued at $169,592. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its position in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Cellebrite DI in the third quarter valued at about $40,000. First Horizon Corp increased its position in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the last quarter. Finally, Vestcor Inc acquired a new stake in shares of Cellebrite DI in the third quarter valued at about $70,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.